US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Warren Buffett holdings

2,533.50

+16.920.67%

Number of Gainers:33

Number of Losers:8

Number of Flat:2

PE:- -

High:2,540.96

Open:2,514.43

Low:2,503.61

Close:2,516.58

Loading ...

Verizon to speak at Deutsche Bank Conference March 11

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Bristol-Myers Squibb Says Opdivo With Yervoy Approved in EU to Treat Liver Cancer

MT Newswires Live

VeriSign's (NASDAQ:VRSN) investors will be pleased with their respectable 45% return over the last five years

Simply Wall St.

Goldman Traders Say Stock Rally Hinges on Knife-Edge Jobs Data

Johnson & Johnson Unit's Lazertinib With Amivantamab Approved in UK for Non-Small Cell Lung Cancer

MT Newswires Live

Balanced Outlook for Kroger: Opportunities Amidst Leadership Changes and Market Volatility

SPY, VOO, or QQQ: Discover Which ETF Reigns Supreme for U.S. Investors

Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer

American Express (NYSE:AXP) Will Pay A Larger Dividend Than Last Year At $0.82

Simply Wall St.

BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab)

Howard Marks expects a lower return from the S&P 500 over the next decade. Here's what he likes better.

Gap Inc’s Strong Performance and Strategic Focus Drive Buy Rating

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Unresectable or Advanced Hepatocellular Carcinoma

THOMSON REUTERS

Kroger Company: Promising Growth Prospects Amidst Challenging Consumer Environment

Buy Rating for Synchrony Financial: Attractive Valuation and Enduring Mitigants Drive Confidence

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4559/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4559"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4559\",,,,,undefined,":{"symbol":"BK4559","market":"US","secType":"PLATE","nameCN":"Warren Buffett holdings","latestPrice":2533.5,"timestamp":1741381199999,"preClose":2516.5808,"halted":0,"volume":561762460,"delay":0,"changeRate":0.006723,"change":16.919189,"pbRate":6.468398,"amount":106041181773.59647,"amplitude":0.014843,"prevYearClose":2550.9072,"fiveDayClose":2602.9524,"twentyDayClose":2599.454,"turnoverRate":0.007632,"marketCap":12420738104320,"floatMarketCap":11799476916096,"peRate":28.445411},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4559\",,,,,undefined,":{"symbol":"BK4559","high":2540.9607,"amplitude":0.014843,"preClose":2516.5808,"low":2503.6062,"pbRate":"6.468398","latestPrice":2533.5,"volume":561762460,"delay":0,"open":2514.4326,"prevYearClose":2550.9072,"prevWeekClose":2602.9524,"prevMonthClose":2602.9524,"prevQuarterClose":2550.9072,"fiveDayClose":2602.9524,"twentyDayClose":2599.454,"sixtyDayClose":2581.7395,"secType":"PLATE","market":"US","turnoverRate":0.007632,"peRate":28.445411,"marketCap":12420738104320,"floatMarketCap":11799476916096,"timestamp":1741381199999,"nameCN":"Warren Buffett holdings"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4559\",,,,undefined,":{"bkCode":"BK4559","up":33,"down":8,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4559\",pageSize:16,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517480571","title":"Verizon to speak at Deutsche Bank Conference March 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480571","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480571?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"NEW YORK, March  07, 2025  (GLOBE NEWSWIRE) -- Frank Boulben, senior vice president and chief revenue officer for the Consumer Group of Verizon (NYSE, Nasdaq: VZ), is scheduled to speak at the Deutsch","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038901/0/en/Verizon-to-speak-at-Deutsche-Bank-Conference-March-11.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051811.HKD","BK4533","LU0306806265.USD","LU1066051498.USD","LU2384288077.EUR","LU0868494708.USD","LU1621768206.USD","LU1066053197.SGD","LU0320765646.SGD","LU1066051225.USD","LU0321505439.SGD","BK4585","VZ","LU1585245621.USD","LU1621768115.EUR","BK4550","LU0942090050.USD","LU0985481810.HKD","IE00BSNM7G36.USD","LU1366192091.USD","BK4559","LU1699723380.USD","LU1162221912.USD","LU0306807586.USD","LU1621767810.EUR","BK4515","LU1571399168.USD","BK4552","LU0225284248.USD","BK4581","BK4118","BK4534","BK4588","LU0098860793.USD","LU1059921491.USD","LU1621767737.EUR","LU0321505868.SGD","LU0868494617.USD","BK4115","LU1430594728.SGD","DB","LU1914381329.SGD","BK4566","LU0225771236.USD"],"gpt_icon":0},{"id":"2517480505","title":"InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480505?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"JENA, Germany, March  07, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038913/0/en/InflaRx-Showcases-Vilobelimab-s-Role-in-Immuno-Dermatology-at-the-2025-AAD-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4139","IE00BWXC8680.SGD","LU0094547139.USD","LU1868837300.USD","BK4558","BK4581","SG9999015358.SGD","LU1430594728.SGD","USA","BK4504","LU0234572021.USD","LU0689626769.HKD","PD","SG9999014567.USD","BK4568","LU0061475181.USD","BK4567","LU1066053197.SGD","LU1169589451.USD","IE00BBT3K403.USD","SG9999002232.USD","LU1868837136.USD","LU1868836914.USD","LU1929549753.HKD","SG9999002224.SGD","BK4533","SG9999015341.SGD","IE00B3T34201.USD","BNTX","BK4181","LU2552382215.SGD","ARDS","LU0234570918.USD","LU2129689514.USD","PG","SG9999014575.USD","LU1066051498.USD","PK","LU1585245621.USD","LU1162221912.USD","IE00BLSP4239.USD","SG9999001440.SGD","BK4535","BK4018","LU1868836591.USD","BK4559","LU0868494617.USD","LU2129689431.USD","SG9999014542.SGD"],"gpt_icon":0},{"id":"2517487820","title":"Bristol-Myers Squibb Says Opdivo With Yervoy Approved in EU to Treat Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517487820","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517487820?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:53","pubTimestamp":1741351995,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb  said Friday the European Commission has approved Opdivo plus Yervoy as the first-line treatment for adults with unresectable or advanced hepatocellular carcinoma, the most common type of liver cancer.The company said the approval applies across all 27 EU member states, along with Iceland, Liechtenstein, and Norway.Bristol-Myers Squibb said the approval is based on a phase 3 clinical study that showed dual immunotherapy treatment with Opdivo, or nivolumab, and Yervoy, or ipilimumab, resulted in median overall survival of 23.7 months and overall response rate of 36.1%.In the US, the company said its supplemental Biologics License Application for Opdivo plus Yervoy in unresectable hepatocellular carcinoma has a target action date of April 21.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0096364046.USD","BK4007","BK4534","LU2125154778.USD","LU0306806265.USD","BK4585","IE00BFTCPJ56.SGD","LU1585245621.USD","LU1670710588.SGD","LU1989771016.USD","LU0321505439.SGD","LU1074936037.SGD","LU1291159041.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1670711040.USD","LU2133065610.SGD","LU1868837300.USD","BK4581","LU1718418525.SGD","LU1868836914.USD","LU1261432733.SGD","LU1868836591.USD","LU1868836757.USD","LU2360032135.SGD","BK4156","IE00B2B36J28.USD","LU1093756325.SGD","LU1571399168.USD","IE00BFXG1179.USD","LU2242646821.SGD","LU1093756168.USD","BK4532","LU2125154935.USD","LU1670711123.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU0225771236.USD","LU0456855351.SGD","BK4588","LU1868837136.USD","LU0321505868.SGD","LU0225284248.USD","LU0306807586.USD","IE00BSNM7G36.USD","BMY","LU0061475181.USD","LU0985481810.HKD","BK4559"],"gpt_icon":0},{"id":"2517480385","title":"VeriSign's (NASDAQ:VRSN) investors will be pleased with their respectable 45% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480385","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480385?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:37","pubTimestamp":1741351051,"startTime":"0","endTime":"0","summary":"When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. But VeriSign, Inc.  has fallen short of that second goal, with a share price rise of 45% over five years, which is below the market return. Some buyers are laughing, though, with an increase of 25% in the last year.So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share  with the share price.Over half a decade, VeriSign managed to grow its earnings per share at 10.0% a year. This EPS growth is higher than the 8% average annual increase in the share price. So ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verisigns-nasdaq-vrsn-investors-pleased-123731670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","TSYW.SI","TQQQ","PSQ","LU0823417737.USD","QLD","LU0950375773.USD","IE00BGHQF748.EUR","LU1043141396.HKD","NVIW.SI","LU2506952170.USD","LU2506951958.HKD","IE00B3QW5Z07.USD","BK4112","USAW.SI","LU0234570918.USD","USJW.SI","LU2210150020.SGD","LU1043141123.HKD","BK4588","BK4116","LU0426417589.USD","LU2210149790.SGD","LU0348723411.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","BK4559","VRSN","LU1121112475.USD","LU2095319765.USD","LU2506952097.USD","LU2506951875.HKD","BK4532","LU0823417653.USD","LU1571399168.USD","LU0994945656.USD","MNQmain","SQQQ","QID",".IXIC","NQmain","LU0426412945.USD"],"gpt_icon":1},{"id":"2517471484","title":"Goldman Traders Say Stock Rally Hinges on Knife-Edge Jobs Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2517471484","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517471484?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:26","pubTimestamp":1741350413,"startTime":"0","endTime":"0","summary":"Investor sentiment is so poor that even a slightly better-than-expected US jobs report is set to spark a rally in the S&P 500, according to a Goldman Sachs Group Inc. trading desk.","market":"fut","thumbnail":"https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/UCGOLVVM5RBEFPAUFYBFAX2WEM.jpg","type":0,"news_type":0,"thumbnails":["https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/UCGOLVVM5RBEFPAUFYBFAX2WEM.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/business/company-news/2025/03/07/goldman-traders-say-stock-rally-hinges-on-knife-edge-jobs-data/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["LU0061475181.USD","LU2237443978.SGD","BK4550","LU2237438978.USD","IVV","LU2237443895.HKD","BK4533","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU2471134523.USD","IE0004086264.USD","LU0096364046.USD","IE0002270589.USD","LU2237443465.HKD","UPRO","LU2471134879.HKD","LU2237443622.USD","VOO","ESmain","IE00BFXG1179.USD","LU1868836914.USD",".SPX","LU1868837300.USD","LU2471134796.USD","OEX","IE0034235188.USD","BK4581","LU1868836591.USD","LU1868837136.USD","LU2750360641.GBP","SSO","BK4127","IE00B19Z3581.USD","LU2750360997.AUD","OEF","BK4534","LU1791807156.HKD","SPY","LU1668664300.SGD","SDS","LU2471134952.CNY","SH","SPXU","BK4585","BK4588","IE0004091025.USD","LU0106831901.USD","LU2237443549.SGD","BK4559","LU2237443382.USD"],"gpt_icon":0},{"id":"2517849094","title":"Johnson & Johnson Unit's Lazertinib With Amivantamab Approved in UK for Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517849094","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517849094?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:25","pubTimestamp":1741350310,"startTime":"0","endTime":"0","summary":"Johnson & Johnson's (JNJ) Janssen-Cilag subsidiary has received marketing authorization in the UK for lazertinib combined with amivantamab to treat adults with a type of non-small cell lung cancer, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2089984988.USD","BK4504","IE0009355771.USD","LU1935042991.SGD","LU2129689605.HKD","IE00B2B36J28.USD","LU0122379950.USD","LU1061106388.HKD","BK4532","JNJ","SG9999001440.SGD","LU0345770993.USD","LU1221951129.SGD","LU1585245621.USD","LU0640476718.USD","BK4581","LU2430703095.HKD","LU1066053197.SGD","LU2133065610.SGD","LU0345770308.USD","LU1267930813.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","LU1280957306.USD","BK4559","LU1196500208.SGD","SG9999002224.SGD","BK4534","LU1244550221.USD","LU1261432733.SGD","LU1032466523.USD","LU1506573853.SGD","LU2602419157.SGD","LU1778281490.HKD","LU0234572021.USD","LU0320765646.SGD","LU0345769631.USD","LU1674673428.USD","IE00BVYPNW00.USD","LU1066051225.USD","LU1032955483.USD","LU1894683348.USD","BK4533","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2517548459","title":"Balanced Outlook for Kroger: Opportunities Amidst Leadership Changes and Market Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2517548459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517548459?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:17","pubTimestamp":1741349827,"startTime":"0","endTime":"0","summary":"Kroger Company (KR – Research Report), the Consumer Defensive sector company, was revisited by a Wall Street analyst today. Analyst Simeon Gutman f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-outlook-for-kroger-opportunities-amidst-leadership-changes-and-market-volatility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-outlook-for-kroger-opportunities-amidst-leadership-changes-and-market-volatility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4113","BK4504","LU0312595415.SGD","LU0302445910.USD","LU0345770308.USD","BK4533","LU1201861249.SGD","LU0345770993.USD","LU0477156953.USD","BK4559","LU0648001328.SGD","BK4585","KR","LU0980610538.SGD","LU0130102774.USD","BK4532","LU0130517989.USD","BK4588","LU2275660780.HKD"],"gpt_icon":0},{"id":"2517556484","title":"SPY, VOO, or QQQ: Discover Which ETF Reigns Supreme for U.S. Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2517556484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517556484?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:14","pubTimestamp":1741349689,"startTime":"0","endTime":"0","summary":"Exchange-traded funds (ETFs) have become a mainstay of today’s financial markets, offering easy and instant diversification, low costs, and reliabl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/article/spy-voo-or-qqq-discover-which-etf-reigns-supreme-for-u-s-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/article/spy-voo-or-qqq-discover-which-etf-reigns-supreme-for-u-s-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4166","SPXU","VOO",".SPX","BK4534","BK4559","OEX","BK4211","LU1861220207.SGD","ISBC","SSO","BK4588","SDS","FDN","LU1791807156.HKD","BK4504","ESmain","OEF","LU0106831901.USD","BK4581","UPRO","IVV","LU1668664300.SGD","LU1861217088.USD","SPY","SH","LU2360107671.USD","BK4585","DFS","BK4550"],"gpt_icon":0},{"id":"2517828944","title":"Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517828944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517828944?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:12","pubTimestamp":1741349520,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer.Bristol Myers on Friday said the approval covers the combination for the first-line treatment of adults with unresectable or advanced hepatocellular carcinoma.Liver cancer is the third most frequent cause of cancer death worldwide, and hepatocellular carcinoma is the most common type of liver cancer, accounting for 90% of global cases, the Princeton, N.J., biopharmaceutical company said.The Opdivo/Yervoy combination is already approved in several cancer indications worldwide. The U.S. Food and Drug Administration is reviewing the combination as a potential first-line treatment option for adults with unresectable hepatocellular carcinoma, with a target action date of April 21.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU1093756325.SGD","LU1323610961.USD","LU1868836914.USD","LU2360032135.SGD","LU1093756168.USD","IE00BFXG1179.USD","LU1868837300.USD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU0882574055.USD","LU1670710661.SGD","LU1670711040.USD","LU0321505439.SGD","BK4126","BK4585","LU1291159041.SGD","LU2125154778.USD","LU0114720955.EUR","LU1585245621.USD","LU0985481810.HKD","MYE","IE00BSNM7G36.USD","BK4559","LU0306807586.USD","LU1868836591.USD","LU1032466523.USD","LU2125154935.USD","LU1571399168.USD","BMY","BK4581","BK4534","LU1670711123.USD","LU1868836757.USD","BK4007","LU1718418525.SGD","LU1989771016.USD","LU1261432733.SGD","LU1074936037.SGD","LU2133065610.SGD","IE00B2B36J28.USD","LU2242652126.USD","IE00BJT1NW94.SGD","LU0321505868.SGD","LU0868494617.USD","LU1430594728.SGD","LU0456855351.SGD","LU0225771236.USD","LU1670710588.SGD","BK4532"],"gpt_icon":0},{"id":"2517430575","title":"American Express (NYSE:AXP) Will Pay A Larger Dividend Than Last Year At $0.82","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430575","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517430575?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:07","pubTimestamp":1741349224,"startTime":"0","endTime":"0","summary":"American Express Company ( NYSE:AXP ) has announced that it will be increasing its dividend from last year's comparable...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/92001-main-header/1585188293644","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/92001-main-header/1585188293644"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/diversified-financials/nyse-axp/american-express/news/american-express-nyseaxp-will-pay-a-larger-dividend-than-las-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2552382058.USD","LU0310799852.SGD","LU2361044865.SGD","BK4166","LU0011850046.USD","BK4588","LU0980610538.SGD","LU1778281490.HKD","IE00BFSS8Q28.SGD","LU1917777945.USD","LU0211327993.USD","LU0130102774.USD","IE00BJJMRX11.SGD","LU0266013472.USD","IE00B7KXQ091.USD","IE00B775H168.HKD","IE0004445015.USD","IE00BFSS7M15.SGD","LU1861217088.USD","LU1674673428.USD","IE00BJJMRY28.SGD","LU1201861249.SGD","IE00BN29S564.USD","LU2106854487.HKD","AXP","IE0005OL40V9.USD","LU0094547139.USD","BK4585","NYSE","BK4559","LU0868494708.USD","LU0868494617.USD","LU2361045086.USD","LU0648001328.SGD","LU1674673691.USD","LU2360107671.USD","LU2552382215.SGD","LU1974910355.USD","LU1267930490.SGD","LU1861220207.SGD","LU0942090050.USD","LU2361044949.HKD","IE00BSNM7G36.USD","IE00B4JS1V06.HKD","LU2461242641.AUD","LU0211328371.USD","LU2023250504.SGD","LU2552382132.HKD"],"gpt_icon":0},{"id":"2517648909","title":"BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517648909","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517648909?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348832,"startTime":"0","endTime":"0","summary":"BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) March 7 (Reuters) - Bristol-Myers Squibb Co BMY.N:BRISTOL MYERS SQUIBB RECEIVES EUROPEA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1032466523.USD","LU1093756168.USD","LU0456855351.SGD","LU1718418525.SGD","BK4559","LU0868494617.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU0321505439.SGD","LU2125154935.USD","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU1868837300.USD","LU0061475181.USD","BMY","IE0002141913.USD","LU0114720955.EUR","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4585","LU0225771236.USD","BK4534","LU0096364046.USD","LU1074936037.SGD","LU2125154778.USD","BK4532","LU1323610961.USD","LU2133065610.SGD","LU0237698245.USD","LU0985481810.HKD","LU1670711040.USD","IE0009355771.USD","LU0882574055.USD","LU1430594728.SGD","LU1868837136.USD","LU1093756325.SGD","LU1868836757.USD","LU1670710588.SGD","LU0306807586.USD","LU1571399168.USD","LU2242652126.USD","LU1670711123.USD","LU1868836591.USD","LU0306806265.USD","BK4588","BK4007","IE00BSNM7G36.USD","LU1585245621.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2517481494","title":"Howard Marks expects a lower return from the S&P 500 over the next decade. Here's what he likes better.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481494?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"Credit returns are dependable and reliable, says the billionaire investor. Investors looking for more solid longer-term returns should be looking at credit - and not banking on the S&P 500 to get them there, according to billionaire investor Howard Marks.That's as the yield on the 10-year Treasury BX:TMUBMUSD10Y is higher than the S&P 500's earnings yield, that is the ratio of earnings to price, the inverse of the P/E, he said. \"And if Treasurys are poised to out-yield the S&P 500, high-yield bonds will do so to an even greater extent.\". \"We'd rather buy at higher yields and wider spreads, and we may get a chance to do so ... or not. But that preference in itself isn't a reason for not increasing allocations to credit today,\" he said.But he doesn't believe that private credit \"represents a systemic risk,\" since private-loan portfolios and owners are far less levered than banks were just before the crisis, and loan holders haven't sold each other default protection or other hedging, unl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US30Y.BOND","OEX","SDS",".SPX","HBMD","US5Y.BOND","BK4585","SPXU","BK4559","VOO","US6M.BOND","SSO","IVV","BK4211","BK4504","OEF","US3Y.BOND","BK4581","ESmain","BK4550","SH","BK4534","US7Y.BOND","SPY","US10Y.BOND","US12M.BOND","UPRO","US2Y.BOND","BK4588"],"gpt_icon":0},{"id":"2517481882","title":"Gap Inc’s Strong Performance and Strategic Focus Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481882?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348777,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Ike Boruchow maintained a Buy rating on Gap Inc (GAP – Research Report) yesterday and set a price target of $30.00. Ike Borucho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/gap-incs-strong-performance-and-strategic-focus-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/gap-incs-strong-performance-and-strategic-focus-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","LU1791807156.HKD","LU0477156953.USD","BK4501","LU0742534661.SGD","LU0640476718.USD","LU0256863811.USD","LU0683600562.USD","LU2361045086.USD","LU0106831901.USD","LU0149725797.USD","LU1267930227.SGD","LU0267386448.USD","LU0708994859.HKD","LU1069347547.HKD","LU0048573561.USD","LU1074936037.SGD","LU2461242641.AUD","LU0211327993.USD","IE00B7SZLL34.SGD","LU0310800965.SGD","BK4559","LU0175139822.USD","LU0787776722.HKD","LU0072461881.USD","LU1506573853.SGD","LU0289960550.SGD","LU0648001328.SGD","LU0128525689.USD","LU0128525929.USD","LU1201861249.SGD","LU0310799852.SGD","LU1668664300.SGD","LU2236285917.USD","LU0029864427.USD","BK4504","LU1267930573.SGD","IE00B19Z3581.USD","LU0310800379.SGD","LU0162691827.USD","BK4585","IE0002270589.USD","LU0052756011.USD","LU0211328371.USD","LU1267930490.SGD","BK4207","LU1280957306.USD","LU0980610538.SGD","IE00B19Z3B42.SGD","LU0070302665.USD"],"gpt_icon":0},{"id":"2517891474","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517891474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517891474?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348745,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU0225284248.USD","LU1868836757.USD","LU0868494617.USD","LU1291159041.SGD","LU0225771236.USD","LU2133065610.SGD","LU1718418525.SGD","BK4585","LU1670710661.SGD","LU0321505868.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU2360032135.SGD","LU2125154778.USD","BK4559","LU1032466523.USD","LU0306807586.USD","LU1868836591.USD","LU1868836914.USD","LU1670711040.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1261432733.SGD","LU1670710588.SGD","LU1093756168.USD","IE0002141913.USD","LU0985481810.HKD","BK4581","LU1430594728.SGD","IE00BFXG1179.USD","LU0096364046.USD","LU0114720955.EUR","LU1571399168.USD","LU1868837300.USD","LU2242652126.USD","BK4534","LU0306806265.USD","LU0061475181.USD","LU1989771016.USD","LU0321505439.SGD","IE00B2B36J28.USD","LU1093756325.SGD","LU1074936037.SGD","LU2125154935.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU1868837136.USD","BMY","LU0882574055.USD"],"gpt_icon":0},{"id":"2517885481","title":"Kroger Company: Promising Growth Prospects Amidst Challenging Consumer Environment","url":"https://stock-news.laohu8.com/highlight/detail?id=2517885481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517885481?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:56","pubTimestamp":1741348591,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Edward Kelly maintained a Buy rating on Kroger Company (KR – Research Report) yesterday and set a price target of $73.00. Edwar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kroger-company-promising-growth-prospects-amidst-challenging-consumer-environment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kroger-company-promising-growth-prospects-amidst-challenging-consumer-environment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","LU1201861249.SGD","IE00B7SZLL34.SGD","LU0256863811.USD","BK4113","LU0312595415.SGD","LU0310799852.SGD","IE00B19Z3581.USD","LU1267930227.SGD","LU0640476718.USD","LU0787776722.HKD","BK4504","LU1506573853.SGD","LU1267930573.SGD","LU2361045086.USD","BK4585","KR","LU0106831901.USD","LU0029864427.USD","LU0289960550.SGD","LU0267386448.USD","LU0302445910.USD","LU2236285917.USD","LU0175139822.USD","LU0648001328.SGD","LU0345770993.USD","LU0980610538.SGD","LU0128525689.USD","BK4501","LU1791807156.HKD","BK4533","LU1069347547.HKD","LU2275660780.HKD","LU0708994859.HKD","LU0683600562.USD","LU0211327993.USD","LU0477156953.USD","LU1074936037.SGD","LU1668664300.SGD","BK4207","LU0310800965.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0048573561.USD","BK4559","LU0128525929.USD","LU0211328371.USD","LU0742534661.SGD","LU0052756011.USD","LU0162691827.USD"],"gpt_icon":0},{"id":"2517818214","title":"Buy Rating for Synchrony Financial: Attractive Valuation and Enduring Mitigants Drive Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2517818214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517818214?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:51","pubTimestamp":1741348287,"startTime":"0","endTime":"0","summary":"Analyst Mihir Bhatia from Bank of America Securities reiterated a Buy rating on Synchrony Financial (SYF – Research Report) and keeping the price t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-synchrony-financial-attractive-valuation-and-enduring-mitigants-drive-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-synchrony-financial-attractive-valuation-and-enduring-mitigants-drive-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0648000940.SGD","LU1162221912.USD","LU0234572021.USD","LU1883839398.USD","LU0787776722.HKD","IE00B7SZLL34.SGD","LU0320765646.SGD","LU0052756011.USD","BK4559","LU0306806265.USD","LU0128525689.USD","IE00BLSP4239.USD","BK4504","LU0306807586.USD","LU2129689605.HKD","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","LU0477156797.USD","LU1894683264.USD","LU2133065610.SGD","LU0256863902.USD","LU0310800965.SGD","IE00BLSP4452.SGD","LU1201861249.SGD","LU1267930227.SGD","LU0256863811.USD","LU0053666078.USD","IE00B19Z3581.USD","LU1880398471.USD","IE00BKVL7J92.USD","LU0320765489.SGD","LU1791807156.HKD","IE00B19Z3B42.SGD","LU0321505439.SGD","LU1894683348.USD","LU0106831901.USD","LU0868494617.USD","LU0640476718.USD","LU1366192091.USD","LU1201861165.SGD","LU0321505868.SGD","LU1506573853.SGD","LU0130518102.USD","IE00BFXG1179.USD","LU0170899867.USD","LU1718418525.SGD","LU1074936037.SGD","IE0002270589.USD","LU1668664300.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":95,"pageCount":9,"totalSize":1506}]}}